Core Insights - Alumis Inc. is a clinical stage biopharmaceutical company focused on developing oral therapies for immune-mediated diseases, with a precision approach to optimize clinical outcomes [5][6] - The company announced two data presentations for its drug A-005, a selective TYK2 inhibitor, at the ACTRIMS Forum 2025 [1][2] Group 1: A-005 Drug Development - A-005 is a potent, selective, CNS-penetrant TYK2 inhibitor aimed at treating neuroinflammatory diseases, including multiple sclerosis and Parkinson's Disease [4] - The Phase 1 clinical trial of A-005 involved 135 healthy participants and demonstrated safety, tolerability, and pharmacokinetics, with plans for a Phase 2 trial in multiple sclerosis patients in the second half of 2025 [3][4] - A-005 is the first reported allosteric TYK2 inhibitor capable of crossing the blood-brain barrier, targeting pro-inflammatory cytokine pathways [2][4] Group 2: Upcoming Presentations - The presentations on A-005 will take place on February 28, 2025, with specific titles and times for each poster session [2] - The first presentation will focus on A-005's modulation of astrocytes and microglia, while the second will cover its safety, tolerability, and pharmacokinetics in healthy volunteers [2] Group 3: Company Overview - Alumis is leveraging a proprietary precision data analytics platform to build a pipeline of molecules for various immune-mediated diseases [5][6] - The company's most advanced product candidate, ESK-001, is being evaluated for moderate-to-severe plaque psoriasis and systemic lupus erythematosus [5]
Alumis Presents Additional Phase 1 Data at ACTRIMS Forum 2025 Supporting Potential of A-005 as First-in-Class CNS Penetrant TYK2 Inhibitor for Treatment of Neuroinflammatory and Neurodegenerative Diseases